Back to Stakeholders
Categories
1 domain / 2 areas / 2 specializations
ProNovo Therapeutics
Also known as: ProNovo
Data updated
Enterprise Intelligence
Quarterly psychedelic drug-development briefing
Compare indication activity, programme milestones, competitive intensity, and near-term catalysts. Q2 includes quarter-over-quarter changes against the published Q1 baseline.
ProNovo Therapeutics is a San Diego-based precision-neuropsychiatry biotechnology company, founded in 2023, developing small-molecule therapeutics for disorders including major depressive disorder and schizophrenia. Its founding team previously discovered and developed the esketamine nasal spray Spravato at Janssen, giving it deep roots in the dissociative and psychedelic-adjacent neuropsychiatry space.
Ecosystem
1 connectionInvestors
JLS FundJLS Fund - What We’re Reading, Issue #03
Fund investment
Quick Facts
- Website
- Visit